240 related articles for article (PubMed ID: 20099300)
1. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N
Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300
[TBL] [Abstract][Full Text] [Related]
2. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
3. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Arai J; Goto K; Stephanou A; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Morimoto S; Kaise Y; Lim LA; Yoshida H; Kato N
J Gastroenterol Hepatol; 2018 May; 33(5):1075-1081. PubMed ID: 29055152
[TBL] [Abstract][Full Text] [Related]
4. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Zhou C; Liu J; Li Y; Liu L; Zhang X; Ma CY; Hua SC; Yang M; Yuan Q
FEBS Lett; 2011 Jun; 585(12):1828-34. PubMed ID: 21530512
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
6. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding.
Arai J; Goto K; Otoyama Y; Nakajima Y; Sugiura I; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Nozawa H; Nakagawa R; Muroyama R; Kato N; Yoshida H
Cancer Immunol Immunother; 2021 Jan; 70(1):203-213. PubMed ID: 32683508
[TBL] [Abstract][Full Text] [Related]
7. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Tsunematsu H; Aono S; Shimizu S; Kodama T; Hikita H; Yamamoto M; Oze T; Aketa H; Hosui A; Miyagi T; Ishida H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
Cancer Immunol Immunother; 2012 Sep; 61(9):1425-32. PubMed ID: 22302133
[TBL] [Abstract][Full Text] [Related]
9. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
[TBL] [Abstract][Full Text] [Related]
10. Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10.
Otoyama Y; Arai J; Goto K; Nozawa H; Nakagawa R; Muroyama R; Sugiura I; Nakajima Y; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Kato N; Yoshida H
Anticancer Res; 2021 May; 41(5):2307-2320. PubMed ID: 33952456
[TBL] [Abstract][Full Text] [Related]
11. Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
Ogawa K; Chiba T; Nakamura M; Arai J; Zhang J; Ma Y; Qiang NA; Ao J; Yumita S; Ishino T; Kan M; Iwanaga T; Nakagawa M; Fujiwara K; Sakuma T; Kanzaki H; Koroki K; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Kondo T; Nakagawa R; Ogasawara S; Muroyama R; Nakamoto S; Kanda T; Maruyama H; Kato J; Matsumoto S; Arai T; Motohashi S; Kato N
Anticancer Res; 2023 Mar; 43(3):1043-1052. PubMed ID: 36854524
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Kuo TC; Lu HP; Chao CC
Biochem Pharmacol; 2011 Jul; 82(2):184-94. PubMed ID: 21549688
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
17. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
